Abstract
Following a single oral or intravenous administration of the R,R(+) andS,S(−) 14C-pseudoracemate of (±)-(1′R*,3R*)-3-phenyl-1-[(1′,2′,3′,4′-tetrahydro-5′,6′-methylene-dioxy-1′-naphthalenyl) methyl] pyrrolidine methanesulfonate (ABT-200/I) to dogs, a total of six (R,R[+]) and eight (S,S[−]) metabolites were identified by high-pressure liquid chromatography/mass spectral techniques. Greater than 99% of the dose was eliminated as metabolites indicating that the clearance of I was predominantly metabolic. The catechol was the major excreted metabolite (fecal), whereas the urine and bile predominantly contained metabolites resulting from secondary biotransformation of the catechol via O-methylation, glucuronidation, and sulfation. After a single 12 mg/kg oral dose of racemic I to dogs, the mean area under the plasma curve (AUC0–24h) averaged 4.55 μg · h/ml, with an apparent plasma clearance value of 2.70 l/h · kg. After 14 daily doses, the apparent plasma clearance was 3.5-fold lower (0.78 l/h · kg) and the AUC0–24h about 4-fold higher (18.58 μg · h/ml). Isolation of liver microsomes from these animals indicated that a cytochrome P450 (P450)-metabolite complex (MI complex) was formed in the liver after both single and multiple dosing. The mean concentration of the MI complex 24 h after a single dose averaged 31 pmol/mg of microsomal protein, whereas the amount in the animals given multiple doses of I averaged 163 pmol/mg. There was a positive correlation (R2 = 0.993) between the plasma AUC for I and the amount of the MI complex found in the liver of each animal. Formation of the MI complex was demonstrated in vitro in control dog liver microsomes, was NADPH-dependent, and was dissociated from P450 with 2-methylbenzimidazole. In vitro preincubation studies indicated that I was a mechanism-based inhibitor and that formation of the complex inhibited catechol formation. These results demonstrate that the liver P450s that metabolize I form an inhibitory MI complex after in vivo administration in dogs. Formation of the complex increases during multiple dosing and inhibits the enzymes from further metabolism of I resulting in nonlinear pharmacokinetics.
Footnotes
- Abbreviations used are::
- ABT-200/I
- (±)-(1′R*,3R*)-3-phenyl-1-[(1′,2′,3′,4′-tetrahydro-5′,6′-methylene-dioxy-1′-naphthalenyl) methyl] pyrrolidine methanesulfonate
- P450
- cytochrome P450
- HPLC
- high-performance liquid chromatography
- AUC
- area under the curve
- ESI-MS
- electrospray ionization-mass spectrometry
- MS/MS
- tandem mass spectometry
- Received August 14, 2001.
- Accepted March 26, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|